Tuberculous Meningitis in a Patient with Crohn's Disease, Which was Treated with Infliximab.
- Author:
Youn Ho KIM
1
;
Beom Jae LEE
;
Jong Jae PARK
;
Won Woo LEE
;
Woo Sik HAN
;
Sung Nam OH
;
Do Won CHOI
;
Jae Seon KIM
;
Young Tae BAK
;
Hee Jin CHEONG
Author Information
1. Department of Gastroenterology, Korea University Medical Center Guro Hospital, Seoul, Korea. gi7pjj@yahoo.co.kr
- Publication Type:Case Report ; Clinical Trial
- Keywords:
Crohn's disease;
Tuberculous meningitis;
Infliximab
- MeSH:
Adult;
Crohn Disease*;
Humans;
Opportunistic Infections;
Sensitivity and Specificity;
Tuberculosis;
Tuberculosis, Meningeal*;
Tumor Necrosis Factor-alpha;
Infliximab
- From:Korean Journal of Gastrointestinal Endoscopy
2007;34(6):339-342
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Clinical trials of tumor necrosis factor (TNF) inhibitor have demonstrated significant efficacy in those patients with Crohn's disease that is not responsive to other anti-inflammatory drug. Infliximab is a human-murine chimeric monoclonal antibody with a high binding affinity and specificity for TNF-alpha. Yet therapy with infliximab is associated with an increased risk of opportunistic infection, and especially tuberculosis. Here we reported on a case of tuberculous meningitis in 26-year-old man, and he was treated with infliximab for uncontrolled and fistulous Crohn's disease. We also include a review of the literature.
